Volume 89 Issue 44 | p. 21 | Concentrates
Issue Date: October 31, 2011

Biogen And Portola Target Arthritis

Department: Business
Keywords: small molecules, arthritis, drug discovery

Biogen Idec and Portola Pharmaceuticals will collaborate to develop Portola’s small-molecule Syk inhibitors for the treatment of autoimmune and inflammatory diseases including rheumatoid arthritis. Biogen will provide Portola with $45 million up front and could make additional payments of up to $509 million. The collaboration’s lead molecule, PRT062607, is in Phase I studies. Biogen Idec’s product line today consists entirely of biologic drugs.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment